A background and critical analysis of the treatment of pneumocystis carinii pneumonia (PCP) in HIV/AIDS.
Mitchell
Brett
B
North Glamorgan NHS Trust, United Kingdom.
D017088:AIDS-Related Opportunistic Infections / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy*; D000890:Anti-Infective Agents / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000981:Antiprotozoal Agents / Q000627:therapeutic use; D001706:Biopsy; D001999:Bronchoscopy; D018791:CD4 Lymphocyte Count; D002981:Clindamycin / Q000627:therapeutic use; D003622:Dapsone / Q000627:therapeutic use; D003906:Developing Countries; D004359:Drug Therapy, Combination; D014943:Global Health; D006801:Humans; D010102:Oxygen Inhalation Therapy; D018579:Patient Selection; D010419:Pentamidine / Q000627:therapeutic use; D011020:Pneumonia, Pneumocystis / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy*; D011241:Prednisone / Q000627:therapeutic use; D011319:Primaquine / Q000627:therapeutic use; D016896:Treatment Outcome; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000627:therapeutic use
D000890:Anti-Infective Agents; D000893:Anti-Inflammatory Agents; D000981:Antiprotozoal Agents; D002981:Clindamycin; D010419:Pentamidine; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D003622:Dapsone; D011319:Primaquine; D011241:Prednisone